Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBITDA Margin (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of EBITDA Margin data on record, last reported at 29.34% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1216.0% year-over-year to 29.34%; the TTM value through Dec 2025 reached 2.35%, up 2765.0%, while the annual FY2025 figure was 2.35%, 2765.0% up from the prior year.
  • EBITDA Margin reached 29.34% in Q4 2025 per APLS's latest filing, down from 47.08% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 47.08% in Q3 2025 and bottomed at 35216.69% in Q2 2021.
  • Average EBITDA Margin over 5 years is 2280.17%, with a median of 127.27% recorded in 2023.
  • The widest YoY moves for EBITDA Margin: up 3425412bps in 2022, down -47743bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 245.5% in 2021, then plummeted by -194bps to 722.94% in 2022, then soared by 91bps to 62.2% in 2023, then soared by 72bps to 17.18% in 2024, then crashed by -71bps to 29.34% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 29.34% in Q4 2025, 47.08% in Q3 2025, and 23.34% in Q2 2025.